BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kuypers DR, Peeters PC, Sennesael JJ, Kianda MN, Vrijens B, Kristanto P, Dobbels F, Vanrenterghem Y, Kanaan N; ADMIRAD Study Team. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation. 2013;95:333-340. [PMID: 23263559 DOI: 10.1097/tp.0b013e3182725532] [Cited by in Crossref: 149] [Cited by in F6Publishing: 44] [Article Influence: 16.6] [Reference Citation Analysis]
Number Citing Articles
1 Belaiche S, Décaudin B, Dharancy S, Noel C, Odou P, Hazzan M. Factors relevant to medication non-adherence in kidney transplant: a systematic review. Int J Clin Pharm 2017;39:582-93. [PMID: 28374343 DOI: 10.1007/s11096-017-0436-4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
2 Bunthof KLW, Al-Hassany L, Nakshbandi G, Hesselink DA, van Schaik RHN, Ten Dam MAGJ, Baas MC, Hilbrands LB, van Gelder T. A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients. Clin Transl Sci 2021. [PMID: 34905302 DOI: 10.1111/cts.13206] [Reference Citation Analysis]
3 Dew MA, Posluszny DM, DiMartini AF, Myaskovsky L, Steel JL, DeVito Dabbs AJ. Posttransplant Medical Adherence: What Have We Learned and Can We Do Better? Curr Transplant Rep 2018;5:174-88. [PMID: 30416933 DOI: 10.1007/s40472-018-0195-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
4 Maier M, Takano T, Sapir-Pichhadze R. Changing Paradigms in the Management of Rejection in Kidney Transplantation: Evolving From Protocol-Based Care to the Era of P4 Medicine. Can J Kidney Health Dis 2017;4:2054358116688227. [PMID: 28270929 DOI: 10.1177/2054358116688227] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
5 Han A, Min SI, Ahn S, Min SK, Hong HJ, Han N, Kim YS, Ahn C, Ha J. Mobile medication manager application to improve adherence with immunosuppressive therapy in renal transplant recipients: A randomized controlled trial. PLoS One 2019;14:e0224595. [PMID: 31689320 DOI: 10.1371/journal.pone.0224595] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
6 Popoola J, Greene H, Kyegombe M, MacPhee IA. Patient involvement in selection of immunosuppressive regimen following transplantation. Patient Prefer Adherence 2014;8:1705-12. [PMID: 25525347 DOI: 10.2147/PPA.S38987] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
7 González-Vílchez F, Delgado JF, Palomo J, Mirabet S, Díaz-Molina B, Almenar L, Arizón JM, Rangel-Sousa D, Pérez-Villa F, Garrido IP, de la Fuente L, Gómez-Bueno M, Sanz ML, Crespo-Leiro MG. Conversion From Immediate-Release Tacrolimus to Prolonged-Release Tacrolimus in Stable Heart Transplant Patients: A Retrospective Study. Transplant Proc 2019;51:1994-2001. [PMID: 31227301 DOI: 10.1016/j.transproceed.2019.04.028] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Suh SW, Lee KW, Jeong J, Kim H, Yi NJ, Suh KS. Risk Factors for the Adverse Events after Conversion from Twice-Daily to Once-Daily Tacrolimus in Stable Liver Transplantation Patients. J Korean Med Sci 2016;31:1711-6. [PMID: 27709847 DOI: 10.3346/jkms.2016.31.11.1711] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
9 Richards VL, Johnson CK, Blosser CD, Sibulesky L. Strategies to Improve Patient Engagement in Young Kidney Transplant Recipients: A Review. Ann Transplant 2018;23:654-8. [PMID: 30224627 DOI: 10.12659/AOT.910698] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 van Zanten R, de Weerd A, Betjes M, Boer-Verschragen M, Massey EK. Is simplification of immunosuppressive medication a way to promote medication adherence of kidney transplant recipients? Findings from a randomized controlled trial. Transpl Int 2021;34:1703-11. [PMID: 34448273 DOI: 10.1111/tri.13993] [Reference Citation Analysis]
11 Larpparisuth N, Skulratanasak P, Vongwiwatana A, Premasathian N. Effect on Dosage Change and Intrapatient Variability After Conversion From Twice-Daily to Once-Daily Tacrolimus Among Thai Kidney Transplant Patients With and Without CYP3A4/5 Inhibitors. Transplant Proc 2019;51:2620-3. [PMID: 31474450 DOI: 10.1016/j.transproceed.2019.02.065] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Albano L, Banas B, Klempnauer JL, Glyda M, Viklicky O, Kamar N. OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. Transplantation. 2013;96:897-903. [PMID: 23982340 DOI: 10.1097/tp.0b013e3182a203bd] [Cited by in Crossref: 52] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
13 Ortega F, Díaz-Corte C, Valdés C. Adherence to immunosuppressor medication in renal transplanted patients. World J Clin Urol 2015; 4(1): 27-37 [DOI: 10.5410/wjcu.v4.i1.27] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Montalescot G, Brotons C, Cosyns B, Crijns HJ, D'Angelo A, Drouet L, Eberli F, Lane DA, Besse B, Chan A, Vicaut E, Darius H; AEGEAN Study Investigators. Educational Impact on Apixaban Adherence in Atrial Fibrillation (the AEGEAN STUDY): A Randomized Clinical Trial. Am J Cardiovasc Drugs 2020;20:61-71. [PMID: 31243691 DOI: 10.1007/s40256-019-00356-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
15 Rahamimov R, Tifti-Orbach H, Zingerman B, Green H, Schneider S, Chagnac A, Mor E, Fox BD, Rozen-Zvi B. Reduction of exposure to tacrolimus trough level variability is associated with better graft survival after kidney transplantation. Eur J Clin Pharmacol 2019;75:951-8. [PMID: 30762079 DOI: 10.1007/s00228-019-02643-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
16 Gelder TV, Etsouli O, Moes DJ, Swen JJ. Comparison of the Impact of Pharmacogenetic Variability on the PK of Slow Release and Immediate Release Tacrolimus Formulations. Genes (Basel) 2020;11:E1205. [PMID: 33076474 DOI: 10.3390/genes11101205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
17 Fernandez Rivera C, Calvo Rodríguez M, Poveda JL, Pascual J, Crespo M, Gomez G, Cabello Pelegrin S, Paul J, Lauzurica R, Perez Mir M, Moreso F, Perelló M, Andres A, González E, Fernandez A, Mendiluce A, Fernández Carbajo B, Sanchez Fructuoso A, Calvo N, Suarez A, Bernal Blanco G, Osuna A, Ruiz-Fuentes MC, Melilli E, Montero Perez N, Ramos A, Fernández B, López V, Hernandez D; Better study. Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study. Clin Transplant 2021;:e14550. [PMID: 34851532 DOI: 10.1111/ctr.14550] [Reference Citation Analysis]
18 Ho B, Bhagat H, Schwartz JJ, Atiemo K, Daud A, Kang R, Montag SE, Zhao L, Lee E, Skaro AI, Ladner DP. Real-World Study of Once-Daily, Extended-Release Tacrolimus Versus Twice-Daily, Immediate-Release Tacrolimus in Kidney Transplantation: Clinical Outcomes and Healthcare Resource Utilization. Adv Ther 2019;36:1465-79. [PMID: 30941724 DOI: 10.1007/s12325-019-00904-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
19 Sabbatini M, Garofalo G, Borrelli S, Vitale S, Torino M, Capone D, Russo L, Pisani A, Carrano R, Gallo R, Federico S. Efficacy of a reduced pill burden on therapeutic adherence to calcineurin inhibitors in renal transplant recipients: an observational study. Patient Prefer Adherence 2014;8:73-81. [PMID: 24470756 DOI: 10.2147/PPA.S54922] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 2.9] [Reference Citation Analysis]
20 Liu B, Liu Y, Yang G, Xu Z, Chen J. Ursolic acid induces neural regeneration after sciatic nerve injury. Neural Regen Res 2013;8:2510-9. [PMID: 25206561 DOI: 10.3969/j.issn.1673-5374.2013.27.002] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
21 Yau WP, Loh CW, Vathsala A. Conversion from Twice-Daily Prograf® to Once-Daily Advagraf® in Multi-ethnic Asian Adult Renal Transplant Recipients With or Without Concomitant Use of Diltiazem: Impact of CYP3A5 and MDR1 Genetic Polymorphisms on Tacrolimus Exposure. Eur J Drug Metab Pharmacokinet 2019;44:481-92. [PMID: 30471066 DOI: 10.1007/s13318-018-0531-5] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Muduma G, Odeyemi I, Smith-Palmer J, Pollock RF. Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence. Patient Prefer Adherence. 2014;8:391-399. [PMID: 24729687 DOI: 10.2147/ppa.s60213] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
23 Sánchez Fructuoso A, Ruiz JC, Franco A, Diekmann F, Redondo D, Calviño J, Serra N, Aladrén MJ, Cigarrán S, Manonelles A, Ramos A, Gómez G, González Posada JM, Andrés A, Beneyto I, Muñiz AL, Perelló M, Lauzurica R. Effectiveness and safety of the conversion to MeltDose® extended-release tacrolimus from other formulations of tacrolimus in stable kidney transplant patients: A retrospective study. Clin Transplant 2020;34:e13767. [PMID: 31815310 DOI: 10.1111/ctr.13767] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
24 Tremblay S, Alloway RR. Clinical Evaluation of Modified Release and Immediate Release Tacrolimus Formulations. AAPS J 2017;19:1332-47. [PMID: 28717926 DOI: 10.1208/s12248-017-0119-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
25 Guirado L, Burgos D, Cantarell C, Fernández A, Franco A, Gentil MÁ, Mazuecos A, Torregrosa JV, Huertas EG, Ruiz JC, Plumed JS, Paul J, Lauzurica R, Zárraga S, Osuna A, Jiménez C, Alonso Á, Rodríguez A, Bardají B, Hernández D. Medium-Term Renal Function in a Large Cohort of Stable Kidney Transplant Recipients Converted From Twice-Daily to Once-Daily Tacrolimus. Transplant Direct 2015;1:e24. [PMID: 27500226 DOI: 10.1097/TXD.0000000000000536] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Vondrak K, Parisi F, Dhawan A, Grenda R, Webb NJA, Marks SD, Debray D, Holt RCL, Lachaux A, Kelly D, Kazeem G, Undre N. Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus. Clin Transplant 2019;33:e13698. [PMID: 31436896 DOI: 10.1111/ctr.13698] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Lieb M, Schiffer M, Erim Y. Optimization of Electronically Monitored Non-Adherence in Highly Adherent Renal Transplant Recipients by Reducing the Dosing Frequency - A Prospective Single-Center Observational Study. Patient Prefer Adherence 2020;14:1389-401. [PMID: 32821087 DOI: 10.2147/PPA.S258131] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Fellström B, Holmdahl J, Sundvall N, Cockburn E, Kilany S, Wennberg L. Adherence of Renal Transplant Recipients to Once-daily, Prolonged-Release and Twice-daily, Immediate-release Tacrolimus-based Regimens in a Real-life Setting in Sweden. Transplant Proc 2020;52:3238-45. [PMID: 33218668 DOI: 10.1016/j.transproceed.2020.06.002] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Kim YH, Chiang YJ, Kim SJ, Kim MS, Park SB, Wu ST, Horita K, Nakashima Y, Jiang H, Han DJ. Safety and Efficacy of Reduced Prolonged-release Tacrolimus Exposure in De Novo Kidney Transplantation: A Randomized, Open-label, Pilot Study in Asia-OPTIMIZE Study. Transplant Direct 2019;5:e340. [PMID: 30993185 DOI: 10.1097/TXD.0000000000000877] [Reference Citation Analysis]
30 Muduma G, Shaw J, Hart WM, Odeyemi A, Odeyemi I. Cost utility analysis of immunosuppressive regimens in adult renal transplant recipients in England and Wales. Patient Prefer Adherence 2014;8:1537-46. [PMID: 25395839 DOI: 10.2147/PPA.S69461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
31 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Hebral AL, Bellière J, Kamar N. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World J Gastroenterol 2018; 24(16): 1795-1802 [PMID: 29713132 DOI: 10.3748/wjg.v24.i16.1795] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
32 Lee EC, Kim SH, Park SJ. Safety and Efficacy of Once-Daily Prolonged-Release Tacrolimus in Living Donor Liver Transplantation: An Open-Label, Prospective, Single-Arm, Phase 4 Study. Ann Transplant 2018;23:713-20. [PMID: 30310047 DOI: 10.12659/AOT.910618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
33 Duncan S, Annunziato RA, Dunphy C, LaPointe Rudow D, Shneider BL, Shemesh E. A systematic review of immunosuppressant adherence interventions in transplant recipients: Decoding the streetlight effect. Pediatr Transplant 2018;22. [PMID: 29218760 DOI: 10.1111/petr.13086] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
34 van Boekel GA, Donders AR, Hoogtanders KE, Havenith TR, Hilbrands LB, Aarnoutse RE. Limited sampling strategy for prolonged-release tacrolimus in renal transplant patients by use of the dried blood spot technique. Eur J Clin Pharmacol 2015;71:811-6. [PMID: 25980838 DOI: 10.1007/s00228-015-1863-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
35 Cheung CY, Chan KM, Tang G, Cheung A, Chak WL. Immunosuppressive Medication Adherence in Kidney Transplant Recipients During the COVID-19 Pandemic: A Cross-Sectional Study in Hong Kong. Transplant Proc 2021;53:2447-50. [PMID: 34481648 DOI: 10.1016/j.transproceed.2021.08.018] [Reference Citation Analysis]
36 Abedini S, Gøransson L, Cockburn E, Kilany S, Holdaas H. Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian Study. Transplant Direct 2018;4:e338. [PMID: 29464199 DOI: 10.1097/TXD.0000000000000755] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
37 Riegersperger M, Plischke M, Jallitsch-Halper A, Steinhauser C, Födinger M, Winkelmayer WC, Dunkler D, Sunder-Plassmann G. A non-randomized trial of conversion from ciclosporin and tacrolimus to tacrolimus MR4 in stable long-term kidney transplant recipients: Graft function and influences of ABCB1 genotypes. PLoS One 2019;14:e0218709. [PMID: 31266056 DOI: 10.1371/journal.pone.0218709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Rubik J, Debray D, Kelly D, Iserin F, Webb NJA, Czubkowski P, Vondrak K, Sellier-Leclerc AL, Rivet C, Riva S, Tönshoff B, D'Antiga L, Marks SD, Reding R, Kazeem G, Undre N. Efficacy and safety of prolonged-release tacrolimus in stable pediatric allograft recipients converted from immediate-release tacrolimus - a Phase 2, open-label, single-arm, one-way crossover study. Transpl Int 2019;32:1182-93. [PMID: 31325368 DOI: 10.1111/tri.13479] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
39 Gustavsen MT, Midtvedt K, Robertsen I, Woillard JB, Debord J, Klaasen RA, Vethe NT, Bergan S, Åsberg A. Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients. Clin Transl Sci 2020;13:1327-35. [PMID: 32652886 DOI: 10.1111/cts.12833] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
40 Lacquaniti A, Campo S, Casuscelli Di Tocco T, Rovito S, Bucca M, Ragusa A, Monardo P. Acute and chronic kidney disease after pediatric liver transplantation: An underestimated problem. Clin Transplant 2020;34:e14082. [PMID: 32949054 DOI: 10.1111/ctr.14082] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Nevins TE, Nickerson PW, Dew MA. Understanding Medication Nonadherence after Kidney Transplant. J Am Soc Nephrol 2017;28:2290-301. [PMID: 28630231 DOI: 10.1681/ASN.2017020216] [Cited by in Crossref: 62] [Cited by in F6Publishing: 19] [Article Influence: 12.4] [Reference Citation Analysis]
42 Chisholm-Burns MA, Spivey CA, Tolley EA, Kaplan EK. Medication therapy management and adherence among US renal transplant recipients. Patient Prefer Adherence 2016;10:703-9. [PMID: 27175070 DOI: 10.2147/PPA.S104646] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
43 Posadas Salas MA, Srinivas TR. Update on the clinical utility of once-daily tacrolimus in the management of transplantation. Drug Des Devel Ther 2014;8:1183-94. [PMID: 25210441 DOI: 10.2147/DDDT.S55458] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
44 Muduma G, Saunders R, Odeyemi I, Pollock RF. Systematic Review and Meta-Analysis of Tacrolimus versus Ciclosporin as Primary Immunosuppression After Liver Transplant. PLoS One 2016;11:e0160421. [PMID: 27812112 DOI: 10.1371/journal.pone.0160421] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
45 Shen CL, Wu BS, Lien TJ, Yang AH, Yang CY. BK Polyomavirus Nephropathy in Kidney Transplantation: Balancing Rejection and Infection. Viruses 2021;13:487. [PMID: 33809472 DOI: 10.3390/v13030487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Muduma G, Shupo FC, Dam S, Hawken NA, Aballéa S, Odeyemi I, Toumi M. Patient survey to identify reasons for non-adherence and elicitation of quality of life concepts associated with immunosuppressant therapy in kidney transplant recipients. Patient Prefer Adherence 2016;10:27-36. [PMID: 26834463 DOI: 10.2147/PPA.S96086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.2] [Reference Citation Analysis]
47 Zaltzman JS, Lai V, Schulz MZ, Moon KH, Cherney DZ. A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers. Transpl Int 2014;27:1294-302. [PMID: 25160518 DOI: 10.1111/tri.12435] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
48 Kim EJ, Kim SJ, Huh KH, Kim BS, Kim MS, Kim SI, Kim YS, Lee J. Clinical significance of tacrolimus intra-patient variability on kidney transplant outcomes according to pre-transplant immunological risk. Sci Rep 2021;11:12114. [PMID: 34108576 DOI: 10.1038/s41598-021-91630-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Sharma A, Cherukuri A, Mehta RB, Sood P, Hariharan S. High Calcineurin Inhibitor Intrapatient Variability Is Associated With Renal Allograft Inflammation, Chronicity, and Graft Loss. Transplant Direct 2019;5:e424. [PMID: 30882028 DOI: 10.1097/TXD.0000000000000862] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
50 Moal V, Grimbert P, Beauvais A, Dubel L, Le Meur Y. A Prospective, Observational Study of Conversion From Immediate- to Prolonged-Release Tacrolimus in Renal Transplant Recipients in France: The OPALE Study. Ann Transplant 2019;24:517-26. [PMID: 31477681 DOI: 10.12659/AOT.916043] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
51 Nguyen C, Dew MA, Irizarry T, McNulty M, Rennick J, Knäuper B, Descoteaux A, Grenier A, Jeannot L, Foster BJ, DeVito Dabbs AJ; all TAKE-IT TOO Investigators. Promoting medication adherence from the perspective of adolescent and young adult kidney transplant recipients, parents, and health care professionals: A TAKE-IT TOO study. Pediatr Transplant 2020;24:e13709. [PMID: 32388916 DOI: 10.1111/petr.13709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Thölking G, Filensky B, Jehn U, Schütte-Nütgen K, Koch R, Kurschat C, Pavenstädt H, Suwelack B, Reuter S, Kuypers D. Increased renal function decline in fast metabolizers using extended-release tacrolimus after kidney transplantation. Sci Rep 2021;11:15606. [PMID: 34341448 DOI: 10.1038/s41598-021-95201-5] [Reference Citation Analysis]
53 Foster BJ, Pai ALH, Zelikovsky N, Amaral S, Bell L, Dharnidharka VR, Hebert D, Holly C, Knauper B, Matsell D, Phan V, Rogers R, Smith JM, Zhao H, Furth SL. A Randomized Trial of a Multicomponent Intervention to Promote Medication Adherence: The Teen Adherence in Kidney Transplant Effectiveness of Intervention Trial (TAKE-IT). Am J Kidney Dis 2018;72:30-41. [PMID: 29602631 DOI: 10.1053/j.ajkd.2017.12.012] [Cited by in Crossref: 54] [Cited by in F6Publishing: 41] [Article Influence: 13.5] [Reference Citation Analysis]
54 Paterson TSE, Demian M, Shapiro RJ, Loken Thornton W. Impact of Once- Versus Twice-Daily Tacrolimus Dosing on Medication Adherence in Stable Renal Transplant Recipients: A Canadian Single-Center Randomized Controlled Trial. Can J Kidney Health Dis 2019;6:2054358119867993. [PMID: 31452902 DOI: 10.1177/2054358119867993] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
55 Usuki S, Uno S, Sugamori H, Tanaka H, Aikawa A. Safety and Effectiveness of Conversion From Cyclosporine to Once-Daily Prolonged-Release Tacrolimus in Stable Kidney Transplant Patients: A Multicenter Observational Study in Japan. Transplantation Proceedings 2018;50:3266-74. [DOI: 10.1016/j.transproceed.2018.06.011] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]